Downclassification Of Implantable Spinal Cord Stimulators Recommended
This article was originally published in The Gray Sheet
Executive Summary
The issue of battery life in the Implantable Pulse Generator (IPG) spinal cord stimulator could best be addressed in labeling, FDA's Neurological Devices Panel agreed Sept. 17 in a 5-1 vote recommending downclassification of the product from Class III to Class II for the indication of pain relief.
You may also be interested in...
FDA Moving Forward On Implantable Spinal Stimulation Downclassification
While FDA views a guidance for implantable spinal cord stimulator (SCS) 510(k) submissions as an appropriate special control, the agency has decided to forego other suggestions made by its Neurological Devices Panel in recommending downclassification of the devices from Class III to Class II.
FDA Moving Forward On Implantable Spinal Stimulation Downclassification
While FDA views a guidance for implantable spinal cord stimulator (SCS) 510(k) submissions as an appropriate special control, the agency has decided to forego other suggestions made by its Neurological Devices Panel in recommending downclassification of the devices from Class III to Class II.
Medtronic Cites FDAMA Clause In Late Hour Bid To Stop IPG Reclassification
FDA cannot retroactively apply Sec. 216 of the FDA Modernization Act and use data contained in a Medtronic Itrel premarket approval application in reclassifying implantable pulse generator for use in treating chronic intractable pain, Medtronic says.